According to the CASTLE trial, the Orsino stent—a biodegradable, ultrathin, sirolimus-eluting stent—provides the same results at 12 months as Xience in angioplasty guided by intravascular imaging. This research was presented at the virtual EuroPCR 2021 Congress. Previous studies (BIOSTEMI and BIOFLOW V) showed that Orsiro was superior to Xience in reducing target-lesion revascularization. However, the reason behind this…
EuroPCR 2021 | EBC MAIN: Provisional Stenting vs. Systematic Dual Stenting in Left Main Coronary Artery
Treating the left main coronary artery with provisional stenting was non-inferior to systematic dual stenting in the EBC MAIN trial, presented at EuroPCR 2021 and simultaneously published in the European Heart Journal. The composite primary endpoint of death, infarction, and target-lesion revascularization was 14.7% for provisional stenting vs. 17.7% for systematic dual stenting (hazard ratio:…
EuroPCR 2021 | COLOR: Complex PCI via Transradial vs Transfemoral Approach
Treating total occlusions, complex bifurcations, grossly calcified lesions or left main lesions via transradial approach is associated with significant reduction in access-site bleeding or vascular complications vs transfemoral approach. This kind of procedures have been typically excluded from studies randomizing patients to transradial vs transfemoral approach. The COLOR study used the transradial bore-guiding catheter Glidesheath…
EuroPCR 2021 | A New Meta-Analysis Challenges the ISCHEMIA Trial
This paper suggests that patients with stable coronary artery disease who undergo elective coronary revascularization find a long-term benefit in terms of cardiac death compared with patients who receive medical treatment alone. These findings, presented at EuroPCR 2021 and simultaneously published in the European Heart Journal, challenge the results from the ISCHEMIA trial. Researchers state…
EuroPCR 2021 | CELEBRATE-02: Novel Glycoprotein IIb/IIIa Inhibitor for ST-Segment Elevation Infarction
Promising fast subcutaneous administration and a quick and potent antiplatelet effect, here comes a novel glycoprotein IIb/IIa inhibitor called RUC-4. This novel drug was tested in the CELEBRATE-02 study, presented at EuroPCR 2021 and simultaneously published in EuroIntervention. The mean platelet inhibition begins 15 minutes after injection and increases with each of the three tested doses…
EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development
According to this recent meta-analysis of randomized studies, ultrathin strut devices are associated with lower rates of target vessel failure vs. 2nd generation drug eluting stents (DES). This advantage was driven by fewer clinically justified reinterventions. This study was published in the European Heart Journal and simultaneously presented at EuroPCR 2021 Scientific Sessions. Ultrathin struts…
EuroPCR 2021 | FUTURE II: Bioresorbable Scaffolds Reloaded
A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to the end point of angiographic in-segment late loss (LL) powered for noninferiority testing. Even though this is a small study with angiographic end points, it might be the first step towards the return of bioresorbable scaffolds. Read also:…